Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migration-dependent extrafollicular programming of pre-plasmablast age-associated B cells drives lupus pathogenesis.

The Journal of clinical investigation·2026
Same author

SATB1 preserves CD4<sup>+</sup> T-cell fidelity and establishes Treg function in antitumor immunity.

Life science alliance·2026
Same author

Characteristics and environmental susceptibility of first-pass meconium microbiota in neonates with congenital intestinal atresia.

Journal of pediatric surgery·2026
Same author

CXCL12-abundant reticular cell lineage is the key source of endosteal osteoblasts and adipocytes in adult bone marrow.

Regenerative therapy·2026
Same author

Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway.

Frontiers in immunology·2026
Same author

A rotavirus vaccine candidate attenuated by codon deoptimization protects neonatal mice against wild-type virus infection.

PLoS pathogens·2026

Related Experiment Video

Updated: Sep 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K

Microbiota-driven antitumour immunity mediated by dendritic cell migration.

Nina Yi-Tzu Lin1,2, Shota Fukuoka1, Shohei Koyama1,3

  • 1Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.

Nature
|July 14, 2025
PubMed
Summary

A novel gut bacterium, Hominenteromicrobium YB328, enhances anti-cancer immunotherapy. This bacterium boosts CD8+ T-cell responses by activating dendritic cells, improving programmed cell death-1 (PD-1) blockade efficacy in mouse models and human cancer patients.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.6K

Related Experiment Videos

Last Updated: Sep 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.6K

Area of Science:

  • Immunology
  • Microbiology
  • Oncology

Background:

  • The gut microbiota's role in immune checkpoint blockade efficacy is recognized but mechanistically unclear.
  • Programmed cell death-1 (PD-1) blockade is a key cancer immunotherapy, but response rates vary.

Purpose of the Study:

  • To elucidate the mechanisms by which gut microbiota influence the efficacy of PD-1 blockade.
  • To identify specific bacterial strains that can augment anti-tumour immune responses.

Main Methods:

  • Isolation and characterization of a novel bacterial strain, Hominenteromicrobium YB328, from patient faeces.
  • In vivo studies using mouse cancer models to assess the effect of YB328 on PD-1 blockade.
  • Analysis of immune cell populations (CD8+ T cells, dendritic cells) and their interactions in tumours and lymphoid tissues.
  • Correlation of YB328 abundance with clinical response and immune cell infiltration in human cancer patients.

Main Results:

  • Hominenteromicrobium YB328 significantly enhanced the antitumour efficacy of PD-1 blockade in mouse models.
  • YB328 activated tumour-specific CD8+ T cells via CD103+CD11b- conventional dendritic cells (cDCs).
  • YB328-stimulated cDCs migrated from the gut to the tumour microenvironment, prolonging T cell engagement.
  • Elevated YB328 abundance in human cancer patients correlated with increased cDC infiltration and favourable PD-1 blockade response.

Conclusions:

  • Hominenteromicrobium YB328 is a potent modulator of anti-tumour immunity, enhancing PD-1 blockade efficacy.
  • The mechanism involves YB328-driven maturation and migration of cDCs, leading to increased tumour-specific CD8+ T cell responses.
  • Targeting or supplementing with YB328 represents a potential strategy to improve cancer immunotherapy outcomes.